



7018 Owensmouth Ave. Suite 103

Canoga Park, CA, 91303

Phone: 818-710-1281

Fax: 818-936-0121

Email: Info@immunospec.com

www.immunospec.com



CKMB

Quantitative determination of Circulating Creatinine Kinase (MB-Isoform) Concentrations in Human Serum

REF

Catalog No.E2-057

IVD

For In Vitro Diagnostic Use Only

SUMMARY AND EXPLANATION OF THE TEST

Creatinine kinase (CK) is an enzyme, found primarily in muscle and brain tissue, which exists as three dimeric isoenzymes CKMM (CK-3), CK-MB (CK-2), and CK-BB (CK-1) — built from subunits designated M and B. The CK-MB isoenzyme, which has a molecular mass of approximately 87,000 daltons, accounts for 5 to 50% of total CK activity in myocardium. In skeletal muscle, by contrast, it normally accounts for just 1% or less, CK-MM being the dominant form, though the percentage can be as high as 10% in conditions reflecting skeletal muscle injury and regeneration (e.g. severe exercise, muscular dystrophy, polymyositis).² Serial measurement of biochemical markers is now accepted universally as an important determinant in ruling in or ruling out acute myocardial infarction. CK-MB is one of the most important myocardial markers (in spite of not being altogether cardiac-specific), with well established roles in confirming acute myocardial infarction (AMI) and in monitoring reperfusion during thrombolytic therapy following AMI.² In AMI, plasma CK-MB typically rises some 3 to 8 hours after the onset of chest pains, peaks within 9 to 30 hours, and returns to baseline levels within 48 to 72 hours. The pattern of serial CK-MB determinations is more informative than a single determination. One CK-MB measurement, even when taken at an appropriate time, cannot definitively confirm or rule out the occurrence of AMI. High levels might reflect skeletal injury rather than myocardial damage. A value within the reference range might be significant if it represents an increase from the patient's baseline levels. Accordingly it has been recommended that CK-MB be measured on admission to the emergency room, and at regulated intervals thereafter. The model described by Heart Emergency Room (ER) Program³ documented that serial testing for CK-MB isoenzyme (OR-MB, EO 2.7; 3.2) (mass on presentation and 3, 6 and 9 hours later in patients with symptoms suggestive of acute ischemic coronary syndrome presenting with a non-diagnostic or equivalent electrocardiogram was more effective (100% sensitivity with 100% negative predictive value) than continuous serial electrocardiograms, electrocardiography and graded exercise testing.

In this method, CK-MB calibrator, patient specimen or control is first added to a streptavidin coated well. Biotinylated monoclonal and enzyme labeled antibodies (directed against distinct and different epitopes of CK-MB) are added and the reactants mixed. Reaction between the various CK-MB antibodies and native CK-MB forms a sandwich complex that binds with the streptavidin binds with the streptavidin coated to the well.

After the completion of the required incubation period, the enzyme-CK-MB antibody bound conjugate is separated from the

unbound enzyme-OR-MB conjugate by aspiration or decantation. The activity of the enzyme present on the surface of the well is quantitated by reaction with a suitable substrate to produce color. The employment of several serum references of known (CKMB) levels permits the construction of a dose response curve of activity and concentration. From comparison to the dose response curve, an unknown specimen's activity can be correlated with OR-MB concentration.

REAGENTS AND MATERIALS PROVIDED:

A. CK-MB Calibrators —1.0 ml/vial (Lyophilized) (A — F) Six (6) vials of references for CK-MB antigen at levels of 0(A), 5(B), 25(C), 100(D), 200(E), and 400(F) ng/ml Reconstitute each vial with 1.0 ml of distilled or demonized water.

The reconstituted calibrators are stable for 7 days at 2-8°C. In order to store for a longer period of time aliquot the reconstituted calibrators in cryo vials and store at -10°C. Do NOT FREEZE THAW MORE THAN ONCE. A preservative has been added

Note: The calibrators, human serum based, were calibrated using gravimetric protein weight from a >99% purified preparation as seen with PAGE.

B. CK-MB Enzyme Reagent —13 ml/vial Icon One vial containing enzyme labeled affinity purified antibody and biotin labeled monoclonal mouse IgG in buffer, dye, and preservative. Store at 2-8 °C.

C. Streptavidin Plate —96 wells

One 96-well microplate coated with streptavidin and packaged in an aluminum bag with a drying agent Store at 2-8 °C.

D. Wash Solution

One (1) vial containing a surfactant in buffered saline. Store at 2-30 °C.

E. Substrate A —7.0 ml/vial

One 1(bottle containing tetramethylbenzidine (TMB) in buffer Store at 2-8 °C.

F. Substrate B --7.0 ml 1 vial

One (1) bottle containing hydrogen peroxide (H2O2) in buffer. Store at 2-8 °C.

G. Stop Solution -- 8.0 ml 1vial

One (1) bottle containing a strong acid (1 NaOH). Store at 2- 30°C.

H. Product Instructions.

Note 1: Do not use reagents beyond the kit expiration date

Note 2: Opened reagents are stable for sixty (60) days when stored at 2-8°C.

Note 3: Above reagents are for a single 96-well microplate.

Required But Not Provided:

- 1 Pipette(s) capable of delivering 25µl and 50 µl volumes with a precision of better than 1.5%.
2. Dispensers for repetitive deliveries of 0.100ml and 0.300ml volumes with a precision of better than 1.5% (optional)
3. Microplate washer or a squeeze bottle (optional)
- 4 Microplate Reader with 450nm and 620nm wavelength absorbance capability (The 620nm Filter is optional)
5. Absorbent Paper for blotting the microplate wells.
6. Plastic wrap or microplate covers for incubation steps
7. Vacuum aspirator (optional) for wash steps.
8. Timer
- 9 Storage containers for storage of wash buffer
10. Distilled or demonized water
- 11 Quality Control Materials

REAGENT PREPARATION:

1 Wash Buffer

Dilute contents of wash solution to 1000ml with distilled or demonized water in a suitable storage container. Store at room temperature 20-27°C for up to 60 days.

2. Working Substrate Solutions

Pour the contents of the amber vial labeled Solution 'A' into the clear vial labeled Solution 'B' Place the yellow cap on the clear vial for easy identification. Mix and label accordingly. Store at 2- 8°C.

Note: Do not use the working substrate if it looks blue.

PRECAUTIONS

For In Vitro Diagnostic Use
Not for Internal or External Use in Humans or Animals

All products that contain human serum have been found to be non-reactive for Hepatitis B Surface antigen, HIV 1&2 and HOV antibodies by FDA licensed reagents. Since no known test can offer complete assurance that infectious agents are absent, all human serum products should be handled as potentially hazardous and capable of transmitting disease. Good laboratory procedures for handling blood products can be found in the Center for Disease Control / National Institute of Health, "Biosafety in Microbiological and Biomedical Laboratories," 2nd Edition, 1988, HHS.

SPECIMEN COLLECTION AND PREPARATION

The specimens shall be blood serum in type and the usual precautions in the collection of venipuncture samples should be observed. The blood should be collected in a plain redtop venipuncture tube without additives or gel barrier. Allow the blood to clot centrifuge the specimen to separate the serum from the cells.

Samples may be refrigerated at 2-8° C for a maximum period of five (5) days. If the specimen(s) cannot be assayed within this time, the sample(s) may be stored at temperatures of -20°C for up to 30 days. Avoid repetitive freezing and thawing. When assayed in duplicate, 0.050 ml of the specimen is required.

TEST PROCEDURE

Before proceeding with the assay, bring all reagents, serum references and controls to room temperature (20 -25 °C).

1. Format the microplates' wells for calibrator, control and patient specimen to be assayed in duplicate. Replace any unused microwell strips back into the aluminum bag, seal and store at 2-8°C.

2. Pipette 0.025 ml (25 µl) of the appropriate calibrators, controls and samples into the assigned wells.

3. Add 0.100 ml (100µl) of the CK-MB Enzyme Reagent to each well. It is very important to dispense all reagents close to the bottom of the microwell.

Note: Use a multichannel pipet to quickly dispense the Enzyme Reagent to avoid drift if the dispensing is to take more than a few minutes.

4. Swirl the microplate gently for 20-30 seconds to mix. Cover with a plastic wrap.

5. Incubate for 15 minutes at room temperature (20-25°C).

6. Discard the contents of the microplate by decantation or aspiration. If decanting, tap and blot the plate dry with absorbent paper.

7. Add 300p1 of wash buffer (see Reagent Preparation Section), decant (tap and blot) or aspirate. Repeat two (2) additional times for a total of three (3) washes. An automatic or manual plate washer can be used. Follow the manufacturer's instruction for proper usage. If a squeeze bottle is used, fill each well to the top by squeezing the container. Avoiding air bubbles. Decant the wash and repeat two (2) additional times.

8. Add 0.100 ml (100µl) of working substrate solution to all wells (see Reagent Preparation Section).

DO NOT SHAKE THE PLATE AFTER SUBSTRATE ADDITION

9. Incubate at room temperature for fifteen (15) minutes.

10. Add (0.050ml) (50µl) of stop solution to each well and mix gently for 15-20 seconds. Read the absorbance in each well at 450nm (using a reference wavelength of 620-630nm to minimize well imperfections) in a microplate reader. The results should be read within thirty (30) minutes of adding the stop solution.

NOTE: Always add reagents in the same order to minimize reaction time differences between wells.


QUALITY CONTROL

Each laboratory should assay controls at levels in the low, normal and elevated range for monitoring assay performance. These controls should be treated as unknowns and values determined in every test procedure performed. Quality control charts should be maintained to follow the performance of the supplied reagents. Pertinent statistical methods should be employed to ascertain trends. Significant deviation from established performance can indicate unnoticed change in experimental conditions or degradation of kit reagents. Fresh reagents should be used to determine the reason for the variations.

EXAMPLE 1

Sample I.D.	Well Number	Abs (A)	Mean Abs (B)	Value (ng/ml)
Cal A	A1	0.022	0.022	0
	B1	0.023		
Cal B	C1	0.072	0.071	5
	D1	0.070		
Cal C	E1	0.243	0.236	25
	F1	0.230		
Cal D	G1	0.851	0.833	100
	H1	0.815		
Cal E	A2	1.503	1.504	200
	B2	1.505		
Cal F	C2	2.567	2.612	400
	D2	2.658		
Ctrl 1	E2	0.046	0.049	2.35
	F2	0.052		
Ctrl 2	G2	0.585	0.592	70.3
	H2	0.598		
Patient	A3	0.140	0.136	12.4
	B3	0.131		

Figure 1



*The data presented in Example 1 and Figure 1 is for illustration only and **should not** be used in lieu of a dose response curve prepared with each assay.

QC PARAMETERS

In order for the say results to be considered valid the following criteria should be met:

1. The absorbance (OD) of calibrator A should be ≤ 0.1
2. The absorbance (OD) of calibrator f should be ≥ 1.3
3. Four out of six quality control pools should be within the

CALCULATION OF RESULTS

A dose response curve is used to ascertain the concentration of CK-MB in unknown specimens.

1. Record the absorbance obtained from the printout of the microplate reader as outlined in Example 1.
2. Plot the absorbance for each duplicate serum reference versus the corresponding CKMB concentration in ng/ml on line or graph paper (do not overage the duplicates of the serum references before plotting).
3. Draw the best-fit curve through the plotted points
4. To determine the concentration of CK-MB for an unknown, locate the average absorbance of the duplicates for each unknown on the vertical axis of the graph, find the intersecting point on the curve, and read the concentration (in ng/ml) from the horizontal

axis of the graph (the duplicates of the unknown may be averaged as indicated) In the following example, the average absorbance (0.136) intersects the dose response curve at (12.4 ng/ml) CK-MB concentration (See Figure 1).

Note: Computer data reduction software designed for IEMA (ELISA) assays may also be used for the data reduction.

LIMITATIONS OF PROCEDURE

1. It is important that the time of reaction in each well is held constant for reproducible results.
2. Pipetting of samples should not extend beyond ten (10) minutes to avoid assay drift.
3. If more than one (1) plate is used, it is recommended to repeat the dose response curve.
4. Addition of the substrate solution initiates a kinetic reaction, which is terminated by the addition of the stop solution. Therefore, the addition of the substrate and the stopping solution should be added in the same sequence to eliminate any time deviation during reaction.
5. Plate readers measure vertically. Do not touch the bottom of the wells.
6. Failure to remove adhering solution adequately in the aspiration or decantation wash step(s) may result in poor replication and spurious results.
7. Highly lipemic, hemolyzed or grossly contaminated specimen(s) should not be used.
8. Patient samples with CK-MB concentrations above 400 ng/ml may be diluted with the zero calibrator and reassayed multiply the value obtained by the dilution factor to obtain the corrected value
9. Use components from the same lot. No intermixing of reagents from different batches.

EXPECTED VALUES

CK-MB values are consistently higher in plasma than in serum; thus, serum is preferred. Compared with fasting values in non-obese non-diabetic individuals! CK-MB levels are higher in obese non-diabetic subjects and lower in trained athletes. Each laboratory is advised to establish its own ranges for normal and abnormal populations. These ranges are always dependent upon locale, population, laboratory, technique and specificity of the method.

Based on the clinical data gathered by Immunospec in concordance with the published literature the following ranges have been assigned. These ranges should be used as guidelines only Adult (Normal) 2.0 – 5.2 ng/ml

PERFORMANCE CHARACTERISTICS

A. Precision

The within and between assay precision of the CK-MB were determined by analyses on three different levels of pool control area. The number (N), mean value X, standard deviation (σ) and coefficient of variation (C.V.) for each of these control sera are presented in Table 2 and Table 3.

TABLE 2

Within Assay Precision (Values in ng/ml)				
SAMPLE	N	X	σ	C.V.
Pool 1	20	0.82	0.07	8.53%
Pool 2	20	12.11	0.59	4.87%
Pool 3	20	58.10	3.74	6.44%

TABLE 3

Between Assay Precision* (Values in ng/ml)				
SAMPLE	N	X	σ	C.V.
Pool 1	20	0.86	0.09	10.4%
Pool 2	20	13.31	1.22	9.16%
Pool 3	20	52.52	2.84	5.45%

*As measured in ten experiments in duplicate over ten days.

B. Accuracy

The CK-MB was compared with a predicate radioimmunoassay assay. Biological specimens from population (symptomatic and asymptomatic) were used (The values ranged from N/D – 86 ng/ml) The total number of such specimens was 124. The data obtained is displayed in Table 4

TABLE 4

Method	Mean (x)	Least Square Regression Analysis	Correlation Coefficient
This Method (y)	12.52	$y = 0.5477 + 0.9946(x)$	0.971
Reference (x)	12.04		

Only slight amounts of bias between the CK-MB and the reference method are indicated by the closeness of the mean values. The least square regression equation and correlation coefficient indicates excellent method agreement.

C. Sensitivity

The sensitivity (detection limit) was ascertained by determining the variability of the 0 ng/ml serum calibrator and using the 2σ (95% certainty) statistic to calculate the minimum dose. The assay sensitivity was found to be 0.5ng/ml.

D. Specificity

The cross-reactivity of the CK-MB method to selected substances was evaluated by adding the interfering substance(s) to a serum matrix at the following concentration(s). The antibody system used did not detect any CK-BB or CK-MM isoforms when tested at very high concentrations.

REFERENCES

1. ddamnJs, Scrsrtman 49, Larch V, etal acute mwcastcsi intarctinnbcreatnekcnam MB imenzwne arch cardian tinpencn i, /3/1+ Cuecn, 'w 1201-6 (1904)
2. Apple F5, PreenLM, 'IDraitine kinane-tcl& detmtion otmyocatiia intarction sc-ct mnnctoring reperhjdor', J C/ic /mmuxoassj, 11,24-9 (1994)
3. Sriaaro 'A, Cctine 6, Leing F'r', st si, 'Diagnostic evdudim ot orsatine kinme-2 mann end mndirs kinsne-3 and -2 instmnr ration in esiv diagneon ot acute myecarclai intarotcen", Gte Ctern, 39,400-03, (1 W3).
4. Brims D5, "Diagnosis ot mute myncardisi intardinn then nlcdetd muncie ratmage in present a corset rerding use otcrestine kirone incenzyrnd', Clix Chew, 36,705 (1909)
5. i3itlerwo,Levin LM, Bit RB,et al, "Badv oetiedion otaccitemyocadisi intrctcon in paler/n presenting utSi ctest pain and nmdcagnostic BCi3n;nnriai CR-Mn semvicng inthe ernemency dnrartmenf", Anx Ereerg 0/ed, 19,1359-to (iwo).
6. Ha,dermn ,up, mark as, McQueen MJ, si si, "indetmmcnshcon ot creatne kinane-2 after eimtrnphnretcn nepreatien accurSe", CNx Chew, 40,177-03(19W).
7. Ratner ASS/yen C, Brctdin. U, 51 ai, "Bs/vdsgindnot acute myseardiia intardinn, acompreincnc uetmeen chemicaia pedistord', Scuedj Coe Lob Icwe 49,633-9(1909).
8. Riysnnc V. John. 'Current status st datecting CR-MO tor patient manament", din Ciii Prod Rev, 4,26-31(1996).
9. Lang, Vltrerotxrg U. ", C/ce Chew, 26,1439-47 (1962).
10. LeeRN, Cnako 0, Bemhsrct P, Bun RJ."Rde',ame otmacm creatne kinore type I and Iwe 2 inoenzym note iaucratny and dinirai date", C/ic Cheer, 40,1270-93(1994)
11. LeeTH, Rouanc3W, Wenberg MC,et at, Sainouttyotroutrneiciniaci criteria tsr diagnnning mwcardcai intarclnn mdhcn 24 iourn ot howtaichecol', ton/etem wed,106, 101-6 (1907).
12. Pentrahini M, "Crealnkinane MB imtorm&', J Cl/c /mmuxoaso,ey, 11,30-4 (1994).
13. Cit/Ore flU, Ranyor JP,LesyRC, nayreMR, RadohR, Hattemar CR, at si, "Arapid diagncntic and treatmert cester he patients *0, ctsst pain in the onernercvrtaparbeent", dcx Emecp Me4 25,1-9(1995).



European Authorized Representative:
CEpartner4U, Esdoornlaan 13, 3951DB Maarn
. The Netherlands. Tel.: +31 (0)6.516.536.26



Manufacturer:

IMMUNOSPEC CORPORATION

7018 Owensmouth Ave. Suite # 103 Canoga Park, C.A. 91303
(818)710-1281